Tis the season of the down round

There’s a long list of growth-stage companies in health-tech that could theoretically IPO if the markets were more friendly. Despite what you’ve been reading in the press, the IPO window is barely open right now for our industry. Even solid companies like Waystar I’m hearing took a valuation haircut with its debut this week, the first health-tech company to go public since 2022. The company said it will use the financing to pay off debt. Needless to say, I’ll be interested to watch what happens next over at Tempus, as it reportedly seeks a $6.1 billion valuation for its IPO.
Why is this such a problem?
Well as Luba Greenwood, a biotech investor friend put it to me recently, there should be three options on the table at any given time for a growth-stage company that needs money:
A fundraise via the private markets
An IPO (essentially a fundraise via the public markets)
M&A
The problem with our sector - and not Luba’s - is that option 2 is still an ‘avoid at all costs’ for most companies, at least until there are more signs that public market investors will be more receptive to these kinds of businesses.
What’s particularly tricky is that this digital health category is still emerging. Per banker friends, these companies are not traditional software businesses and do not compare favorably to them (selling to health care buyers is not the same as it is in most other sectors). These are still heavy services businesses for the most part. But the VCs who backed them are hoping they’re valued differently than traditional health care companies because of the technology aspect to what they do. That positioning is tricky, for reasons that we’ll discuss in this piece, and is still playing out.
Here’s what I’m hearing from bankers, analysts, media, investors and other important stakeholders about how this will all play out in the 2024/2025 timeframe. And where I’d be focusing my energies right now as a growth-stage digital health player.
In biotech, there’s a clear roadmap. Greenwood says that M&A activity is starting to heat back up, which is fundamentally a good thing because it allows private market investors to double down on the next set of new companies developing new molecules today. And the IPO market is also more active. So it’s feeling more healthy, and companies can simultaneously consider all three when they need to raise capital, taking the best option that materializes.
`Upcoming Sessions
Live conversations with the people shaping healthcare.
AMA with Doximity CEO Jeff Tangney
Join Doximity CEO Jeff Tangney for a live Q&A on where clinicians are finding value with AI, how Doximity has evolved, and building a company from zero to IPO.
Office Hours
A live Q&A with Christina Farr and Ruth Reader, exclusively for Second Opinion Premium members. Thursday, November 19, 1:30–2:30 p.m. ET / 10:30–11:30 a.m. PT.
The Shift Left & the Impact of the Midterms on Healthcare
Democrats just took both chambers. Aneesh Chopra, Christopher Kerns and Mike Desjadon join Ruth Reader and Christina Farr live to talk through what they'll try to do on healthcare — and what's actually achievable under a Republican White House.
Is It Finally the Moment for Alternative Health Plans?
Register Here Employers are under growing pressure to control healthcare costs while improving access, outcomes, and the member experience. That has renewed
Type 2 Diabetes & Cardiometabolic Care: Wearables, AI & GLP-1s
Register Here The rise of wearables, GLP-1s, and AI is reshaping treatment for Type 2 diabetes, weight loss, and metabolic disease.
Verifying AI in Medicine: Is Healthcare AI Actually Ready for Deployment?
Is AI ready for real-world clinical care? Dr. Zak Kohane and Protege’s Engy Ziedan debate what it takes to safely trust AI in diagnosis and treatment, from benchmark performance and clinical evidence to whether we’re holding AI to a higher standard than humans.
Why Are Hospitals Hiring Chief AI Officers?
As AI moves from pilots into day-to-day healthcare operations, health systems are having to decide who should actually own the
Where are AI Agents Actually Working in Healthcare, and Why?
While the healthcare industry remains locked in a high-level debate over the theoretical potential of artificial intelligence, a select group of
Top Employers Share What Healthcare Startups Need to Know in 2026
As enterprise health purchasers face volatile medical cost trends and tightening operational margins, the standard vendor pitch of "improved clinical efficiency&